CD53 and acute myeloid leukemia: A proteomic approach has already been used by Kang and colleagues to characterize AML cell-derived EVs from HL-60, KG-1, and THP-1 cell lines that mainly focus their attention on CD53 and CD47 as useful biomarker for AML disease [39].